Clinical Trial: Rifaximin Treatment of Papulopustular Rosacea
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study
Brief Summary: The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.
Detailed Summary:
100 patients will be randomized into two groups.
Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days, and after a 4-week washout period, receive one placebo tablet three times a day for 14 days.
Group B will receive placebo first, and then rifaximin with the same dosage schedule to Group A.
Assessments will be performed before application and 4 weeks after the last dosage, for both of rifaximin and placebo.
Sponsor: University of California, San Francisco
Current Primary Outcome: Investigator's Global Assessment (IGA) Score of Rosacea Symptoms [ Time Frame: 14 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Achieving an IGA score of 0. [ Time Frame: 14 days ]
Original Secondary Outcome: Same as current
Information By: University of California, San Francisco
Dates:
Date Received: April 1, 2011
Date Started: April 2013
Date Completion: December 2014
Last Updated: April 25, 2014
Last Verified: April 2014